Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated May 25, 2026·v1

Heart Failure with Reduced Ejection Fraction

HFrEF (LVEF ≤ 40%) is a progressive clinical syndrome driven by neurohormonal maladaptation. Management centers on the 'four pillars' of GDMT (ARNI, beta-blocker, MRA, SGLT2i), which should be initiated early and titrated to target doses. Device therapy (ICD/CRT) is indicated for persistent dysfunction after 90 days of therapy. Advanced cases require referral for LVAD or transplant.

High Evidence192 references·6,842 words·28 min read·v1
CardiologyHeart FailureHFrEFGDMTEjection Fraction

Quick Reference

RxDrug of choiceFour-pillar GDMT: [[Sacubitril/valsartan]], [[Carvedilol]], [[Spironolactone]], and [[Empagliflozin]]
AltAlternatives[[Enalapril]] (if ARNI not tolerated), [[Hydralazine]] plus [[Isosorbide dinitrate]] (especially in Black patients), [[Vericiguat]]
⊘AvoidNSAIDs, Non-dihydropyridine CCBs ([[diltiazem]], [[verapamil]]), [[Thiazolidinediones]]
DxTest of choiceTransthoracic Echocardiogram (TTE) for LVEF and structural assessment
ScKey score[[NYHA]] Functional Classification and ACC/AHA Staging
→When to referI-NEED-HELP criteria: Inotropes, NYHA III/IV, End-organ dysfunction, Ejection fraction ≤ 35%, Defibrillator shocks, Hospitalizations, Edema/Escalating diuretics, Low blood pressure, Prognostic medication intolerance
HFrEF management requires the rapid, simultaneous initiation of four-pillar GDMT to reduce mortality and promote reverse remodeling, with device therapy considered only after 90 days of medical optimization.
Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome defined by a left ventricular ejection fraction (LVEF) ≤ 40%, representing a state where the heart cannot meet metabolic demands or does so only at the expense of elevated filling pressures. Affecting approximately 6.7 million adults in the United States, HFrEF carries a significant burden, with a 5-year mortality rate approaching 50%. The management paradigm has shifted from sequential therapy to the rapid, simultaneous initiation of 'four-pillar' guideline-directed medical therapy (GDMT), which includes an ARNI, beta-blocker, MRA, and SGLT2 inhibitor. This comprehensive approach targets the maladaptive neurohormonal and inflammatory pathways that drive progressive ventricular remodeling. Early identification of the underlying etiology—whether ischemic, valvular, or toxic—is critical for determining the potential for myocardial recovery and the timing of advanced interventions like device therapy or mechanical circulatory support.

Overview and Recommendations

Background

  • •HFrEF — heart failure with LVEF ≤ 40% — accounts for approximately 50% of the global heart failure population and remains a leading cause of cardiovascular hospitalization and death despite significant therapeutic advances.
  • •The four pillars of GDMT (ARNI, beta-blocker, MRA, and SGLT2 inhibitor) represent a modern paradigm shift following landmark trials like PARADIGM-HF (2014), DAPA-HF (2019), and EMPEROR-Reduced (2020), which collectively demonstrated a relative mortality reduction of nearly 60% when used in combination.
  • •Maladaptive activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS) drives the central pathophysiology, leading to progressive ventricular dilation, interstitial fibrosis, and adverse remodeling that every guideline-directed therapy seeks to arrest or reverse.
  • •Ischemic heart disease is the primary driver in Western populations, accounting for 50-60% of cases; however, non-ischemic etiologies such as hypertension, valvular disease, viral myocarditis, genetic cardiomyopathies, and toxic exposures (e.g., anthracyclines, alcohol) contribute significantly to the global burden.
  • •Prognostic stakes remain high, particularly in the 'vulnerable phase' following an acute decompensation, where 1-year mortality can exceed 18% and readmission rates are high, necessitating aggressive outpatient titration and monitoring of biomarkers like .
  • •Comorbidities are nearly universal and act as prognostic modifiers; iron deficiency affects up to 75% of patients, while chronic kidney disease (CKD) is present in 40-60%, often complicating the titration of RAAS inhibitors due to risks of hyperkalemia and worsening renal function.

Evaluation

  • •Suspect HFrEF in any patient presenting with exertional dyspnea, , paroxysmal nocturnal dyspnea, or unexplained fatigue accompanied by peripheral edema or abdominal bloating.
  • •Examine the patient for signs of congestion and low output, specifically looking for an elevated (JVP), a displaced and sustained apical impulse, and the presence of an S3 gallop, which is highly specific for ventricular filling into a dilated chamber.
  • •Order a 12-lead ECG to assess for rhythm (e.g., ), QRS duration (threshold ≥ 150 ms suggests potential for CRT), and evidence of prior myocardial infarction or left ventricular hypertrophy.
  • •Measure or BNP levels as the primary diagnostic gatekeeper; levels ≥ 1000 pg/mL identify high-risk cohorts, though thresholds should be adjusted downward in patients with obesity and upward in those with advanced age or renal dysfunction.
  • •Perform a transthoracic echocardiogram (TTE) as the gold-standard initial imaging to confirm LVEF ≤ 40%, assess chamber dimensions, and evaluate for concomitant valvular pathology such as secondary .
  • •Assess baseline renal function (eGFR) and serum potassium levels before initiating GDMT, as these parameters dictate the starting doses and titration speed of RAAS inhibitors and MRAs.
  • •Evaluate for iron deficiency by ordering a ferritin level and transferrin saturation (TSAT); deficiency is defined as ferritin < 100 ng/mL or ferritin 100-299 ng/mL with a TSAT < 20%.
  • •Consider cardiac magnetic resonance (CMR) imaging in patients with new-onset heart failure to differentiate between ischemic and non-ischemic etiologies via late gadolinium enhancement (LGE) patterns.
  • •Perform an ischemic workup, typically via coronary angiography or non-invasive stress testing, in all patients with new-onset HFrEF unless a clear non-ischemic cause is already established.
  • •Screen for sleep-disordered breathing and autonomic dysfunction, as these contribute to nocturnal arrhythmias and poor quality of life; heart rate variability (HRV) metrics can provide additional prognostic insight.
  • •Utilize cardiopulmonary exercise testing (CPET) to measure peak oxygen consumption (pVO2) in patients being considered for advanced therapies; a pVO2 < 12-14 mL/kg/min is a key threshold for heart transplant or LVAD referral.
  • •Monitor for 'red flags' indicating cardiogenic shock or rapid decompensation, including a systolic blood pressure < 90 mmHg, resting tachycardia, worsening renal function, or cool extremities.

Management

  • •Initiate the four pillars of GDMT simultaneously or in rapid succession: an ARNI, a beta-blocker, an MRA, and an SGLT2 inhibitor, regardless of the presence of diabetes.
  • •Administer (ARNI) as the preferred RAAS inhibitor; start at 49/51 mg BID (or 24/26 mg BID if ACE-I naive or low SBP) and titrate to the target dose of 97/103 mg BID.
  • •Start a cardioselective beta-blocker such as 3.125 mg BID or 25 mg daily once the patient is euvolemic; titrate every 2 weeks to target doses (e.g., carvedilol 25-50 mg BID).
  • •Add a mineralocorticoid receptor antagonist (MRA) like 12.5-25 mg daily or 25 mg daily, provided potassium is < 5.0 mEq/L and eGFR is > 30 mL/min/1.73 m².
  • •Prescribe an SGLT2 inhibitor, either 10 mg daily or 10 mg daily, which can be started regardless of volume status and provides early protection against heart failure hospitalization.
  • •Manage fluid overload with loop diuretics; start 20-40 mg IV or PO and adjust based on daily weights and JVP, adding a thiazide-like diuretic for sequential nephron blockade if diuretic resistance occurs.
  • •Treat iron deficiency with IV ferric carboxymaltose (e.g., 1000 mg single dose) to improve functional capacity and reduce the risk of heart failure hospitalizations.
  • •Add 2.5 mg daily (titrated to 10 mg) for patients with 'worsening heart failure' defined by a recent hospitalization or the need for outpatient IV diuretics despite GDMT.
  • •Consider 0.125 mg daily for persistent symptoms or rate control in atrial fibrillation, maintaining serum concentrations between 0.5 and 0.9 ng/mL.
  • •Re-evaluate LVEF after 90 days of optimized GDMT to determine the need for an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT).
  • •Implant a CRT-D in patients with LVEF ≤ 35%, NYHA Class II-IV symptoms, and a QRS duration ≥ 150 ms with a pattern to promote reverse remodeling.
  • •Refer patients to an advanced heart failure center if they meet 'I-NEED-HELP' criteria, such as inotrope dependence, end-organ dysfunction, or frequent ICD shocks.
  • •Avoid non-dihydropyridine calcium channel blockers (e.g., , ) and NSAIDs, as these can exacerbate heart failure and promote sodium retention.
  • •Manage atrial fibrillation with a preference for rhythm control (e.g., catheter ablation) in symptomatic patients, as this has been shown to improve LVEF more effectively than rate control alone.
  • •Initiate cardiac rehabilitation once the patient is stable to improve exercise tolerance and combat cardiac cachexia.
  • •Discuss palliative care and ICD deactivation early in the disease course for patients with Stage D heart failure who are not candidates for LVAD or transplant.

Board Review — High Yield

  • •S3 Gallop — Highly specific physical exam finding for HFrEF, representing blood entering a dilated, compliant ventricle.
  • •Reverse Remodeling — The goal of GDMT; characterized by a decrease in LV volumes and an increase in LVEF.
  • •PARADIGM-HF — Landmark trial establishing the superiority of [[sacubitril/valsartan]] over [[enalapril]] in reducing CV death and HF hospitalizations.
  • •90-Day Rule — The required duration of GDMT before primary prevention ICD/CRT implantation to allow for myocardial recovery.
  • •LBBB and QRS ≥ 150 ms — The strongest predictors of a positive response to cardiac resynchronization therapy (CRT).
  • •Iron Deficiency — Defined as Ferritin < 100 or Ferritin 100-299 with TSAT < 20%; requires IV iron replacement in HFrEF.
  • •Cardiorenal Syndrome — Worsening renal function due to venous congestion; often improves with aggressive diuresis rather than fluid administration.
  • •Obesity Paradox — Observation that higher BMI may be associated with lower short-term mortality in established HFrEF, though it remains a risk factor for development.

Deep Dive — Evidence Details

References

  1. [1]

    Zeder K, Brown CH, Santi A et al.. “The prevalence of pulmonary hypertension associated with left heart disease: a systematic review and meta-analysis.” Cardiovascular research (2025). PMID: 41218085 ↗

    L2SR_OBSCited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors
  2. [2]

    Gallone G, Savoca F, Miccoli D et al.. “Stroke in Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis of Randomized Trials.” JACC. Heart failure (2025). PMID: 40088236 ↗

    L1SR_OBSCited in: Definition, Classification, and Epidemiology
  3. [3]

    Karakasis P, Lefkou E, Pamporis K et al.. “Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis.” European journal of heart failure (2025). PMID: 40064512 ↗

    L2SR_OBSCited in: Definition, Classification, and Epidemiology
  4. [4]

    Foà A, Vaduganathan M, Claggett BL et al.. “Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial.” European journal of heart failure (2026). PMID: 41771140 ↗

    L1RCTCited in: Definition, Classification, and Epidemiology, Prognosis, Monitoring, and Palliative Care
  5. [5]

    Horvath CM, Fisser C, Floras JS et al.. “Nocturnal Cardiac Arrhythmias in Heart Failure With Obstructive and Central Sleep Apnea.” Chest (2024). PMID: 39168180 ↗

    L4RCTCited in: Definition, Classification, and Epidemiology
  6. [6]

    Zhang M, Zhou J. “Systematic review and meta-analysis of stroke and thromboembolism risk in atrial fibrillation with preserved vs. reduced ejection fraction heart failure.” BMC cardiovascular disorders (2024). PMID: 39289613 ↗

    L2SR_OBSCited in: Definition, Classification, and Epidemiology
  7. [7]

    Mohamed AA, Andersen CF, Christensen DM et al.. “Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study.” Cardiovascular diabetology (2025). PMID: 40751195 ↗

    L3COHORTCited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors, Pharmacological Management: The Four Pillars of GDMT
  8. [8]

    Culler K, Zelnick LR, Mehta RC et al.. “The ICAM1 p.K56M variant and risk of heart failure in chronic kidney disease: the Chronic Renal Insufficiency Cohort study.” Heart (British Cardiac Society) (2025). PMID: 39915070 ↗

    L2COHORTCited in: Definition, Classification, and Epidemiology
  9. [9]

    Wang H, Gao C, Guignard-Duff M et al.. “Inpatient versus outpatient diagnosis of heart failure across the spectrum of ejection fraction: a population cohort study.” Heart (British Cardiac Society) (2025). PMID: 39880470 ↗

    L3COHORTCited in: Definition, Classification, and Epidemiology
  10. [10]

    Di Lisi D, Madaudo C, Macaione F et al.. “Cancer survivors and cardiovascular diseases: from preventive strategies to treatment.” Journal of cardiovascular medicine (Hagerstown, Md.) (2025). PMID: 39514326 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification, and Epidemiology
  11. [11]

    Pensa AV, Zheng V, Davis L et al.. “Clinical Perspective of Myocardial Recovery and Improvement: Definitions, Prevalence, and Relevance.” Methodist DeBakey cardiovascular journal (2024). PMID: 39184164 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification, and Epidemiology
  12. [12]

    Alnuwaysir RIS, Bomer N, Anker SD et al.. “Iron deficiency definitions and their clinical and prognostic associations across the spectrum of left ventricular ejection fraction in heart failure.” European journal of heart failure (2026). PMID: 41771143 ↗

    L2OTHERCited in: Definition, Classification, and Epidemiology
  13. [13]

    El-Hadidi S, Lindberg F, Benson L et al.. “Magnitude of and outcome associated with inappropriate prescribing in heart failure with reduced ejection fraction: an analysis of 50 348 patients from the Swedish Heart Failure Registry.” European journal of heart failure (2026). PMID: 41771119 ↗

    L3OTHERCited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors
  14. [14]

    Malmborg M, El-Chouli M, Andersen CF et al.. “Associations of body mass index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study (a NorthStar substudy).” Cardiovascular diabetology (2026). PMID: 41606731 ↗

    L2OTHERCited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors
  15. [15]

    Gonzalez-Manzanares R, Anguita-Gámez M, Muñiz J et al.. “Sex Differences in the Diagnosis and Management of Heart Failure Among Outpatients with Type 2 Diabetes.” Journal of women's health (2002) (2026). PMID: 41449991 ↗

    L2OTHERCited in: Definition, Classification, and Epidemiology
  16. [16]

    Gil-Millan P, Gimeno-Orna JA, Rodriguez-Padial L et al.. “HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study.” Cardiovascular diabetology (2025). PMID: 41185008 ↗

    L2OTHERCited in: Definition, Classification, and Epidemiology
  17. [17]

    Borlaug BA, Holse C, Jung MH et al.. “Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.” JACC. Heart failure (2026). PMID: 41099689 ↗

    L4OTHERCited in: Definition, Classification, and Epidemiology
  18. [18]

    Stronati G, Alfieri M, Tombolesi N et al.. “Long-term prognosis of pure and impure tachycardiomyopathy.” ESC heart failure (2025). PMID: 41065522 ↗

    L2OTHERCited in: Definition, Classification, and Epidemiology
  19. [19]

    Lindberg F, Cabrera CC, Benson L et al.. “Iron Deficiency Definitions in Heart Failure Across Ejection Fraction Phenotypes: Prevalence, Symptoms, and Cause-Specific Outcomes.” JACC. Heart failure (2025). PMID: 41045907 ↗

    L3OTHERCited in: Definition, Classification, and Epidemiology
  20. [20]

    Yu Z, Chen Y, Miranda O et al.. “Association of Long-Term Body Mass Index Variability With the Development of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction Across Patterns of Weight Change.” Journal of the American Heart Association (2025). PMID: 40932106 ↗

    L3OTHERCited in: Definition, Classification, and Epidemiology
  21. [21]

    Wu J, Pei Y, Wu J et al.. “Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials.” BMC cardiovascular disorders (2025). PMID: 41023853 ↗

    L1SR_MA_RCTCited in: Etiology and Risk Factors, Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities, Acute Decompensated HFrEF (ADHF)
  22. [22]

    Huang D, Liang J, Zhou Y et al.. “Association of thyroid nodules with comorbidity burden and prognosis in patients with heart failure, anemia, and hyperuricemia: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 41890186 ↗

    L3COHORTCited in: Etiology and Risk Factors, Prognosis, Monitoring, and Palliative Care
  23. [23]

    Yang M, Henderson AD, Anand IS et al.. “Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.” European heart journal. Cardiovascular pharmacotherapy (2025). PMID: 40839760 ↗

    L1RCTCited in: Etiology and Risk Factors
  24. [24]

    Cheng J, Cheng Q, Wu Y et al.. “Association between triglyceride-glucose-body mass index and adverse prognosis in elderly patients with severe heart failure and type 2 diabetes: a retrospective study based on the MIMIC-IV database.” Cardiovascular diabetology (2025). PMID: 40707996 ↗

    L3COHORTCited in: Etiology and Risk Factors, Clinical Presentation and Physical Examination
  25. [25]

    Li JJ, Parajuli DR, Brown J et al.. “Maximum tolerated medication dose and other predictors of mortality in heart failure with reduced ejection fraction: retrospective cohort study.” BMC cardiovascular disorders (2025). PMID: 41146052 ↗

    L3COHORTCited in: Etiology and Risk Factors
  26. [26]

    Antza C, Jordan J, McGowan B et al.. “Treating obesity and heart failure: a how-to-manage guide from the European Association for the Study of Obesity and the European Society of Hypertension working group on diabetes and metabolic risk factors.” Journal of hypertension (2026). PMID: 41818428 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors
  27. [27]

    Nowakowski M, Mazuruk M, Nogajski Ł et al.. “Epicardial adipose tissue as a determinant of heart failure prognosis: insights across ejection fraction phenotypes.” Cardiovascular diabetology (2026). PMID: 41803855 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors, Pathophysiology and Ventricular Remodeling, Prognosis, Monitoring, and Palliative Care
  28. [28]

    Parizad R, Hatwal J, Taban Sadeghi M et al.. “Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.” Vascular health and risk management (2026). PMID: 41953528 ↗

    L1SR_OBSCited in: Etiology and Risk Factors, Pharmacological Management: The Four Pillars of GDMT
  29. [29]

    Garin N, Carballo D, Dash J et al.. “Overweight and obesity association with mortality in patients with heart failure and reduced or preserved ejection fraction-a cohort study.” PloS one (2026). PMID: 41632717 ↗

    L2COHORTCited in: Etiology and Risk Factors
  30. [30]

    Barghash MH. “Sex-Based Differences in Advanced Heart Failure.” Heart failure clinics (2026). PMID: 41895895 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors, Advanced Heart Failure: Inotropes, LVAD, and Transplant
  31. [31]

    Costa TA, Vest AR, Harrington J. “Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure.” Current opinion in cardiology (2026). PMID: 41802118 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors
  32. [32]

    Won Y, Shin MS, Kim E et al.. “Sex- and phenotype-specific prognostic implications of body mass index in acute heart failure.” ESC heart failure (2026). PMID: 41885184 ↗

    L2OTHERCited in: Etiology and Risk Factors, Acute Decompensated HFrEF (ADHF)
  33. [33]

    Johansson JSM, Henrysson J, Basic C et al.. “Biomarkers of iron deficiency and prognosis in patients hospitalised with new-onset heart failure and a reduced left ventricular ejection fraction.” Open heart (2026). PMID: 41856675 ↗

    L3OTHERCited in: Etiology and Risk Factors, Acute Decompensated HFrEF (ADHF)
  34. [34]

    Dempster T, Corker A, Vu K et al.. “Modulation of macrophage polarization with acute administration of Vericiguat after myocardial infarction.” American journal of physiology. Heart and circulatory physiology (2026). PMID: 41693664 ↗

    L5OTHERCited in: Etiology and Risk Factors
  35. [35]

    Otero Garcia O, Donoso Trenado V, de la Fuente-López P et al.. “Renal function trajectories in 'De Novo' heart failure with reduced ejection fraction: impact on outcomes.” Open heart (2026). PMID: 41651561 ↗

    L2OTHERCited in: Etiology and Risk Factors
  36. [36]

    Kim M, Lee J, Yang T et al.. “Peak oxygen consumption as a modifier of the obesity paradox in patients with obesity with heart failure with reduced ejection fraction.” International journal of obesity (2005) (2026). PMID: 41629475 ↗

    L3OTHERCited in: Etiology and Risk Factors
  37. [37]

    Charfeddine S, Hbaieb MA, Laribi N et al.. “Endothelial function: a novel marker to evaluate the prognosis of heart failure with reduced ejection fraction.” American journal of physiology. Heart and circulatory physiology (2026). PMID: 41546611 ↗

    L2OTHERCited in: Etiology and Risk Factors, Diagnostic Evaluation and Multimodality Imaging
  38. [38]

    Kobari Y, Maznyczka A, Khokhar AA et al.. “Clinical Application of Guideline-Directed Medical Therapy in TAVR Patients With Heart Failure and Reduced Ejection Fraction.” JACC. Cardiovascular interventions (2026). PMID: 41534988 ↗

    L2OTHERCited in: Etiology and Risk Factors
  39. [39]

    Song ZQ, Wang BX, Zhou ZB et al.. “Smoking behaviour, altered DNA methylation, and heart failure risk: evidence from a prospective cohort and epigenetic Mendelian randomization study.” Clinical epigenetics (2026). PMID: 41530847 ↗

    L2OTHERCited in: Etiology and Risk Factors
  40. [40]

    Lyu C, Tong X, Fu P et al.. “The hemoglobin glycation index stratifies heart failure phenotypes and in-hospital risk.” Frontiers in endocrinology (2025). PMID: 41473250 ↗

    L3OTHERCited in: Etiology and Risk Factors
  41. [41]

    Chen X, Zhang X, Yang M et al.. “The influence of non-cardiac comorbidities burden on heart failure with improved ejection fraction: Evaluated by Charlson comorbidity index.” International journal of cardiology (2026). PMID: 41314300 ↗

    L3OTHERCited in: Etiology and Risk Factors
  42. [42]

    Siddiqui HF, Waqas SA, Batool RM et al.. “The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis.” Heart failure reviews (2025). PMID: 40399552 ↗

    L1SR_OBSCited in: Pathophysiology and Ventricular Remodeling
  43. [43]

    Ono R, Chimura M, Docherty KF et al.. “Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HF.” JACC. Heart failure (2026). PMID: 41528277 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging, Prognosis, Monitoring, and Palliative Care
  44. [44]

    Madrini V, Souza PVR, Fernandes F et al.. “Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.” Journal of the American College of Cardiology (2026). PMID: 41396086 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging, Prognosis, Monitoring, and Palliative Care
  45. [45]

    Chunawala Z, Patel KV, Garcia KR et al.. “Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study.” JACC. Heart failure (2026). PMID: 41204924 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging
  46. [46]

    Udelson JE, Bělohlávek J, Dukát A et al.. “Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.” JACC. Heart failure (2026). PMID: 41171251 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging
  47. [47]

    Echeverria LE, Bocchi E, Demacq C et al.. “Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.” European journal of heart failure (2025). PMID: 40916703 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging
  48. [48]

    Zannad F, O'Connor CM, Butler J et al.. “Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.” Lancet (London, England) (2025). PMID: 40897188 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging, Acute Decompensated HFrEF (ADHF)
  49. [49]

    Zile MR, Abraham WT, Lindenfeld J et al.. “Mechanistic Basis for Differential Effects of Interatrial Shunt Treatment in HFrEF vs HFpEF: The RELIEVE-HF Trial.” JACC. Cardiovascular imaging (2026). PMID: 40892630 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling
  50. [50]

    Kalogeropoulos AP, Hameed I, Anker SD et al.. “Changes in natriuretic peptide levels following patiromer-enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND study.” European journal of heart failure (2025). PMID: 40607983 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging
  51. [51]

    McDowell K, Welsh P, Docherty KF et al.. “Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40465275 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging
  52. [52]

    Shaddy R, Gong J, Garito T et al.. “Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF.” ESC heart failure (2025). PMID: 40353367 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging
  53. [53]

    Yatsu S, Woo A, Horvath CM et al.. “LV Structure and Function in HFrEF With and Without Peak-Flow-Triggered Adaptive Servo-Ventilation-Treated Sleep-Disordered Breathing.” JACC. Heart failure (2026). PMID: 40310326 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling
  54. [54]

    Docherty KF, McDowell K, Welsh P et al.. “Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.” JACC. Heart failure (2025). PMID: 40088234 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling
  55. [55]

    Marra AM, D'Assante R, De Luca M et al.. “Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled Trial.” JACC. Heart failure (2025). PMID: 40047762 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Clinical Presentation and Physical Examination
  56. [56]

    Wiyono AV, Ardinal AP. “Is Carvedilol Effective in Preventing and Modulating Concentric Cardiac Remodelling? A Comprehensive Systematic Review and Meta-Analyses.” Cardiovascular therapeutics (2025). PMID: 41194854 ↗

    L1SR_OBSCited in: Pathophysiology and Ventricular Remodeling
  57. [57]

    Si F, Liu Q, Ma X et al.. “Effects of Renal Denervation on Cardiac Remodeling, Cardiac Function, and Cardiovascular Neurohormones in Heart Failure with Reduced Ejection Fraction Patients: A Meta-Analysis and Systematic Review.” Cardiorenal medicine (2025). PMID: 40132560 ↗

    L1SR_OBSCited in: Pathophysiology and Ventricular Remodeling
  58. [58]

    Sideris K, Bunsawat K, Brinker L et al.. “The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study.” The American journal of cardiology (2026). PMID: 41765262 ↗

    L1RCTCited in: Pathophysiology and Ventricular Remodeling, Diagnostic Evaluation and Multimodality Imaging, Prognosis, Monitoring, and Palliative Care
  59. [59]

    Russo E, Venturelli E, Leoncini G et al.. “Renal protection in heart failure with reduced ejection fraction: not all that glitters is gold.” European journal of internal medicine (2026). PMID: 41407587 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Ventricular Remodeling, Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  60. [60]

    Madaudo C, Ibrahim W, Noakes D et al.. “The changing landscape of heart failure: translating management into the modern era.” European journal of internal medicine (2026). PMID: 41353033 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Ventricular Remodeling
  61. [61]

    Peck KH, Dulay MS, Hameed S et al.. “Intentional weight loss in overweight and obese patients with heart failure: A systematic review.” European journal of heart failure (2024). PMID: 38752254 ↗

    L1SR_OBSCited in: Clinical Presentation and Physical Examination
  62. [62]

    Chimura M, Jhund PS, Henderson AD et al.. “Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial.” European journal of heart failure (2026). PMID: 41771075 ↗

    L1RCTCited in: Clinical Presentation and Physical Examination, Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities, Prognosis, Monitoring, and Palliative Care
  63. [63]

    Mentz RJ, Butler J, McMullan CJ et al.. “Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial.” European journal of heart failure (2025). PMID: 41020754 ↗

    L1RCTCited in: Clinical Presentation and Physical Examination, Pharmacological Management: The Four Pillars of GDMT
  64. [64]

    Böhm M, Butler J, Abdin A et al.. “Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced.” European journal of heart failure (2025). PMID: 40956156 ↗

    L1RCTCited in: Clinical Presentation and Physical Examination, Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  65. [65]

    Song Z, Wang SY, Qidong Z et al.. “Catheter ablation versus medical rate control for persistent atrial fibrillation in older heart failure patients with reduced ejection fraction.” Heart (British Cardiac Society) (2025). PMID: 40393692 ↗

    L2RCTCited in: Clinical Presentation and Physical Examination, Diagnostic Evaluation and Multimodality Imaging, Management of Congestion and Comorbidities
  66. [66]

    Marallo C, Landra F, Taddeucci S et al.. “Cardiac resynchronization therapy guided by interventricular conduction delay: How to choose between biventricular pacing or conduction system pacing.” Journal of cardiovascular electrophysiology (2024). PMID: 39363418 ↗

    L1RCTCited in: Clinical Presentation and Physical Examination, Device Therapy: ICD and CRT
  67. [67]

    Xing LY, Højberg S, Kriegerg DW et al.. “Heart Failure Events After Long-term Continuous Screening for Atrial Fibrillation: Results From the Randomized LOOP Study.” Circulation. Arrhythmia and electrophysiology (2024). PMID: 39022823 ↗

    L1RCTCited in: Clinical Presentation and Physical Examination
  68. [68]

    Yan Q, Chen X, Yu C et al.. “Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis.” BMC cardiovascular disorders (2024). PMID: 39578752 ↗

    L1SR_OBSCited in: Clinical Presentation and Physical Examination
  69. [69]

    Nagai M, Ewbank H, Nakano Y et al.. “Heart Rate Variability and Heart Failure with Reduced Ejection Fraction: A Systematic Review of Literature.” Current cardiology reviews (2025). PMID: 39492768 ↗

    L2SR_OBSCited in: Clinical Presentation and Physical Examination
  70. [70]

    Li JW, Wang J, Chen Y et al.. “Longitudinal blood pressure and cardiovascular outcomes in heart failure: An individual patient data pooling analysis of clinical trials.” European journal of heart failure (2025). PMID: 40411457 ↗

    L1TRIAL_NONRANDOMCited in: Clinical Presentation and Physical Examination
  71. [71]

    Tang X, He R, Zhang P. “Association between ultra-short-term heart rate variability and atrial fibrillation in heart failure population: a protocol for a prospective observational cohort study.” BMJ open (2025). PMID: 40750283 ↗

    L2COHORTCited in: Clinical Presentation and Physical Examination, Management of Congestion and Comorbidities
  72. [72]

    Wang P, Zhao Y, Wang D et al.. “Relationship between waist-to-height ratio and heart failure outcome: A single-centre prospective cohort study.” ESC heart failure (2025). PMID: 39287135 ↗

    L2COHORTCited in: Clinical Presentation and Physical Examination
  73. [73]

    Currò D, Vergani E, Nicolazzi MA et al.. “Circulating Omentin Levels in Heart Failure: A Case-Control Study.” International journal of molecular sciences (2026). PMID: 42123575 ↗

    L3CASE_CONTROLCited in: Clinical Presentation and Physical Examination
  74. [74]

    Alghamdi M, Dihoum A, Hakami K et al.. “Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes.” Diabetes, obesity & metabolism (2025). PMID: 41053997 ↗

    L1RCTCited in: Diagnostic Evaluation and Multimodality Imaging, Pharmacological Management: The Four Pillars of GDMT
  75. [75]

    Lee S, Claggett BL, Fang JC et al.. “Changes in cardiac structure and function are associated with health-related quality of life in heart failure patients with reduced ejection fraction: Results from the EVALUATE-HF trial.” European journal of heart failure (2025). PMID: 40678912 ↗

    L1RCTCited in: Diagnostic Evaluation and Multimodality Imaging
  76. [76]

    Güder G, Reiter T, Bauer WR et al.. “Cardiac Magnetic Resonance Imaging vs Coronary Angiography as Primary Strategy in Newly Diagnosed Heart Failure.” JACC. Heart failure (2025). PMID: 40652576 ↗

    L1RCTCited in: Diagnostic Evaluation and Multimodality Imaging
  77. [77]

    Özbek BT, Modin D, Sengeløv M et al.. “Left atrial strain and all-cause mortality in patients with heart failure with reduced ejection fraction: a retrospective cohort study.” BMJ open (2026). PMID: 41730559 ↗

    L3COHORTCited in: Diagnostic Evaluation and Multimodality Imaging, Prognosis, Monitoring, and Palliative Care
  78. [78]

    Sticchi A, Vitale C, Bargagna F et al.. “Tricuspid Transcatheter Edge-to-Edge Repair (T-TEER): A Single Approach to a Multiforme Pathology.” Current cardiology reports (2025). PMID: 40802019 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Evaluation and Multimodality Imaging
  79. [79]

    Kaunaitė A, Markevičiūtė A, Barauskas V et al.. “A Comprehensive Profile of Heart Failure Patients Across Ejection Fraction Subtypes: Insights from a Single-Center Retrospective Cohort Study.” Medicina (Kaunas, Lithuania) (2025). PMID: 41010924 ↗

    L3COHORTCited in: Diagnostic Evaluation and Multimodality Imaging
  80. [80]

    Daidone M, Casuccio A, Soldano JS et al.. “Effects of intravenous furosemide plus small-volume hypertonic saline solutions on inflammatory, remodelling markers and epigenetics signatures of patients with congestive acute decompensated heart failure (ADHF).” Aging (2026). PMID: 41915883 ↗

    L1RCTCited in: Diagnostic Evaluation and Multimodality Imaging, Management of Congestion and Comorbidities
  81. [81]

    Alimi H, Tajik A. “The Dilemma in the Management of Patients with Heart Failure with Reduced Ejection Fraction, Sinus Rhythm and Left Ventricular Spontaneous Echo Contrast: A Narrative Review.” Current cardiology reviews (2026). PMID: 40444621 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Evaluation and Multimodality Imaging
  82. [82]

    Kanenawa K, Ando K, Nasu T et al.. “Changes in Natriuretic Peptide Levels and Cardiac Structure in Patients Treated With Vericiguat　- VERIFY-HF Registry.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 41905957 ↗

    L4OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  83. [83]

    Dattilo G, Licordari R, Imbalzano E et al.. “Long-term outcomes following sacubitril/valsartan therapy for chronic HFrEF: an Italian real-world multicentre study.” ESC heart failure (2026). PMID: 41843757 ↗

    L3OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  84. [84]

    Kok TF, Abou Kamar S, Suthahar N et al.. “Serially measured blood biomarkers collected in the context of usual care, predict clinical outcome in a real-life heart failure population.” International journal of cardiology (2026). PMID: 41819192 ↗

    L3OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  85. [85]

    Hashiba M, Hansen MT, Helge JW et al.. “Determinants of changes in peak oxygen consumption in patients with new-onset heart failure.” International journal of cardiology (2026). PMID: 41724449 ↗

    L2OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  86. [86]

    Müller-Kozarez I, Sandek A, Edelmann F et al.. “Baseline characteristics in the TransitionCHF study: asymptomatic patients with heart failure and reduced ejection fraction.” ESC heart failure (2026). PMID: 41711737 ↗

    L2OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  87. [87]

    Östenson B, Bergström E, Steding-Ehrenborg K et al.. “Association between left ventricular longitudinal function and left atrial strain in left ventricular dysfunction.” ESC heart failure (2026). PMID: 41711211 ↗

    L3OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  88. [88]

    Berthelot E, Bauer F, Fauvel C et al.. “Echocardiographic risk stratification in heart failure with post-capillary pulmonary hypertension: prognostic value of LAVI and TAPSE/PASP.” European heart journal. Cardiovascular Imaging (2026). PMID: 41611605 ↗

    L2OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  89. [89]

    Polovina M, Tomić M, Janković M et al.. “Impact of Predischarge NT-proBNP on Treatment Optimisation in Acute Heart Failure.” International journal of molecular sciences (2026). PMID: 41596673 ↗

    L2OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  90. [90]

    Priebe-Brämer H, Jaly F, Rahunathan N et al.. “Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience.” ESC heart failure (2025). PMID: 41255167 ↗

    L3OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  91. [91]

    Matsumoto S, Butt JH, Docherty KF et al.. “Obesity, aldosterone, and natriuretic peptides in patients with heart failure and reduced ejection fraction.” Cardiovascular research (2026). PMID: 41248675 ↗

    L2OTHERCited in: Diagnostic Evaluation and Multimodality Imaging
  92. [92]

    Ferreira JP, Anker SD, Butler J et al.. “Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.” JACC. Heart failure (2026). PMID: 41171249 ↗

    L2RCTCited in: Pharmacological Management: The Four Pillars of GDMT
  93. [93]

    Jiang N, Zhang Y, Tang Y et al.. “Comparative efficacy and safety of different SGLT2 inhibitor-based combination strategies in HFrEF: a systematic review and network meta-analysis.” Frontiers in endocrinology (2025). PMID: 41550872 ↗

    L1SR_OBSCited in: Pharmacological Management: The Four Pillars of GDMT, Prognosis, Monitoring, and Palliative Care
  94. [94]

    van Essen BJ, Ceelen DCH, Ouwerkerk W et al.. “Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.” Journal of the American College of Cardiology (2025). PMID: 40892608 ↗

    L1SR_OBSCited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  95. [95]

    Mendiratta A, Banga A, Garg P et al.. “Sodium-glucose Cotransporter 2 Inhibitors Association with Risk of Heart Failure Hospitalization in Preserved and Mildly Reduced Ejection Fraction, Regardless of Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Current cardiology reviews (2026). PMID: 42117353 ↗

    L1SR_OBSCited in: Pharmacological Management: The Four Pillars of GDMT, Acute Decompensated HFrEF (ADHF)
  96. [96]

    Suzuki K, Osa S, Takeshita S et al.. “Additive Effects of Angiotensin Receptor-Neprilysin Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Neurohormonal Inhibition Therapy in Severe HFrEF: A Systematic Review and Network Meta-analysis.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 41549334 ↗

    L1SR_OBSCited in: Pharmacological Management: The Four Pillars of GDMT
  97. [97]

    Bhandari K, Qadri M, Dhakal R et al.. “The Impact of SGLT2 Inhibitors on Pulmonary Artery Pressures and Pulmonary Hemodynamics in Patients With Heart Failure: A Systematic Review.” Cardiovascular therapeutics (2025). PMID: 41164749 ↗

    L2SR_OBSCited in: Pharmacological Management: The Four Pillars of GDMT
  98. [98]

    Senanayake S, Lee ASY, Graves N et al.. “Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study.” BMJ open (2026). PMID: 41819588 ↗

    L3COHORTCited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  99. [99]

    Ma CH, Qi A, Gagnon L et al.. “Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study.” ESC heart failure (2025). PMID: 41243130 ↗

    L2COHORTCited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  100. [100]

    Khamboonruang S, Bunditboondee P, Jittham P et al.. “Comparative Cardiovascular Outcomes of SGLT2i Plus Low-Dose of Conventional Triple Therapy Versus High-Dose of Conventional Triple Therapy for Heart Failure with Reduced Ejection Fraction (HFrEF): A Retrospective Cohort Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42075652 ↗

    L3COHORTCited in: Pharmacological Management: The Four Pillars of GDMT
  101. [101]

    Peng JR, Chen TH, Chen DY et al.. “SGLT2i with ARNi versus RASi in heart failure with reduced ejection fraction: Improved survival and reduced hyperkalemia risk in a real-world cohort study.” Journal of cardiology (2025). PMID: 40939738 ↗

    L2COHORTCited in: Pharmacological Management: The Four Pillars of GDMT, Acute Decompensated HFrEF (ADHF)
  102. [102]

    Cabrera S, Vivanco D, Lizama D et al.. “[Renal Protection by SGLT2 Inhibitors in Patients with Heart Failure Depends on Ventricular Function: Pooled Analysis and -Analysis].” Revista medica de Chile (2025). PMID: 40668013 ↗

    L1SR_OBSCited in: Pharmacological Management: The Four Pillars of GDMT
  103. [103]

    Brownell N, Solomon N, Greene SJ et al.. “Clinical Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Among Older Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.” Journal of the American Heart Association (2026). PMID: 42132199 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT, Acute Decompensated HFrEF (ADHF)
  104. [104]

    Leszek P, Csanádi Z, Gruev I et al.. “Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).” ESC heart failure (2026). PMID: 41858299 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT
  105. [105]

    Greene SJ, Adam A, Schmedt N et al.. “Contemporary Guideline-Directed Medical Therapy for Heart Failure in the United States: The EMPACE Study.” Journal of the American Heart Association (2026). PMID: 41804888 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  106. [106]

    Kobayashi M, Monzo L, Baudry G et al.. “Real-world data on early initiation of sodium-glucose co-transporter-2 inhibitors in newly diagnosed heart failure with reduced ejection fraction.” ESC heart failure (2026). PMID: 41711250 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT
  107. [107]

    Oliva F, Orso F, Colivicchi F et al.. “Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study.” ESC heart failure (2026). PMID: 41711238 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  108. [108]

    Sauer AJ, Ter Maaten JM, Savarese G. “Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF.” ESC heart failure (2026). PMID: 41711220 ↗

    L5REVIEW_NARRATIVECited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  109. [109]

    Bianco M, Carigi S, De Maria R et al.. “Impact of chronic kidney disease on treatment implementation and prognosis of patients with heart failure: A large retrospective observational analysis from the Italian Network-Heart Failure (IN-HF) registry.” European journal of internal medicine (2026). PMID: 41617596 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  110. [110]

    Greene SJ, Xu H, Chiswell K et al.. “One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge.” JAMA cardiology (2026). PMID: 41604197 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  111. [111]

    Ali MS, Greer KM, Ganai S et al.. “Association of an Algorithm-Generated Medication Optimization Score With Clinical Outcomes in Ambulatory Patients With Heart Failure.” Pharmacotherapy (2026). PMID: 41548207 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT
  112. [112]

    Inciardi RM, Volterrani M, Savarese G et al.. “Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry.” European journal of heart failure (2025). PMID: 41408894 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities
  113. [113]

    Pozzi A, Spoladore R, Iorio A et al.. “Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients' management.” Heart failure reviews (2025). PMID: 41320694 ↗

    L5REVIEW_NARRATIVECited in: Pharmacological Management: The Four Pillars of GDMT, Management of Congestion and Comorbidities, Prognosis, Monitoring, and Palliative Care
  114. [114]

    Ferreira Felix I, Collini M, Fonseca R et al.. “Conduction system pacing versus biventricular pacing in heart failure with reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials.” Heart rhythm (2024). PMID: 38382686 ↗

    L1SR_MA_RCTCited in: Device Therapy: ICD and CRT
  115. [115]

    Zimerman A, Dal Forno A, Rohde LE et al.. “Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial.” JAMA cardiology (2026). PMID: 41811324 ↗

    L1RCTCited in: Device Therapy: ICD and CRT, Prognosis, Monitoring, and Palliative Care
  116. [116]

    Butt JH, Doi SN, Thune JJ et al.. “Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISH.” Journal of the American College of Cardiology (2025). PMID: 41123523 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  117. [117]

    Gouda P, Alemayehu W, Voors AA et al.. “Implantable cardioverter-defibrillators in ischaemic versus non-ischaemic heart failure: Insights from the VICTORIA trial.” European journal of heart failure (2025). PMID: 40539883 ↗

    L2RCTCited in: Device Therapy: ICD and CRT
  118. [118]

    Merkel E, Hatala R, Szigeti M et al.. “Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes.” JACC. Heart failure (2025). PMID: 39614838 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  119. [119]

    Boursiquot BC, Young R, Alhanti B et al.. “Depression and Implantable Cardioverter-Defibrillator Implantation in Black Patients at Risk for Sudden Cardiac Death.” Journal of the American Heart Association (2024). PMID: 38979811 ↗

    L2RCTCited in: Device Therapy: ICD and CRT
  120. [120]

    Merkely B, Hatala R, Merkel E et al.. “Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2024). PMID: 38979560 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  121. [121]

    Yafasova A, Doi SN, Thune JJ et al.. “Effect of Implantable Cardioverter-defibrillators in Nonischemic Heart Failure According to Background Medical Therapy: Extended Follow-up of the DANISH Trial.” Journal of cardiac failure (2024). PMID: 38750689 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  122. [122]

    Karacan MN, Doi SN, Yafasova A et al.. “New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.” European journal of heart failure (2024). PMID: 38733253 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  123. [123]

    Doi SN, Thune JJ, Nielsen JC et al.. “Estimated Glomerular Filtration Rate and Implantable Cardioverter-Defibrillator in Nonischemic Systolic Heart Failure: Extended Follow-Up of DANISH.” Journal of the American Heart Association (2024). PMID: 38293926 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  124. [124]

    Merkely B, Hatala R, Wranicz JK et al.. “Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial.” European heart journal (2023). PMID: 37632437 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  125. [125]

    Segar MW, Keshvani N, Singh S et al.. “Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF.” JACC. Heart failure (2024). PMID: 37565972 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  126. [126]

    Butt JH, Bundgaard JS, Schou M et al.. “Implantable Cardioverter-Defibrillator and Frailty in Non-ischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up of the DANISH Trial.” The American journal of cardiology (2026). PMID: 40998196 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  127. [127]

    Goldenberg I, Zareba W, Ezekowitz JA et al.. “Rationale and design of the comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMP-ICD) trial.” American heart journal (2026). PMID: 40914445 ↗

    L5TRIAL_NONRANDOMCited in: Device Therapy: ICD and CRT
  128. [128]

    Zimerman A, Dal Forno A, Rohde LE et al.. “Conduction system pacing vs biventricular resynchronization in heart failure with reduced ejection fraction and left bundle branch block: Rationale and design of the PhysioSync-HF Trial.” American heart journal (2025). PMID: 40473010 ↗

    L5TRIAL_NONRANDOMCited in: Device Therapy: ICD and CRT, Acute Decompensated HFrEF (ADHF)
  129. [129]

    Flett A, Cebula A, Nicholas Z et al.. “Rationale and study protocol for the BRITISH randomized trial (Using cardiovascular magnetic resonance identified scar as the benchmark risk indication tool for implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy and severe systolic heart failure).” American heart journal (2023). PMID: 37777041 ↗

    L5TRIAL_NONRANDOMCited in: Device Therapy: ICD and CRT
  130. [130]

    Jin C, Dai Q, Li P et al.. “Left bundle branch area pacing for heart failure patients requiring cardiac resynchronization therapy: A meta-analysis.” Journal of cardiovascular electrophysiology (2023). PMID: 37548113 ↗

    L1SR_OBSCited in: Device Therapy: ICD and CRT
  131. [131]

    Prameswari HS, Putra ICS, Kamarullah W et al.. “Role of N-terminal pro-B type natriuretic peptide as a predictor of poor outcomes in patients with HFrEF receiving primary prevention implantable cardioverter-defibrillator therapy: a systematic review and dose-response meta-analysis.” Open heart (2023). PMID: 36927867 ↗

    L1SR_OBSCited in: Device Therapy: ICD and CRT
  132. [132]

    Tint D, Micu S. “One-Year Outcome of Cardiac Contractility Modulation in Patients With Reduced Ejection Fraction, Atrial Fibrillation, and Previous Resynchronization: A Pilot Study.” American journal of therapeutics (Unknown). PMID: 36367992 ↗

    L4TRIAL_NONRANDOMCited in: Device Therapy: ICD and CRT, Advanced Heart Failure: Inotropes, LVAD, and Transplant
  133. [133]

    Fedele D, Casuso Alvarez M, Maida A et al.. “Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials.” European heart journal. Cardiovascular pharmacotherapy (2025). PMID: 40464647 ↗

    L1SR_MA_RCTCited in: Management of Congestion and Comorbidities
  134. [134]

    Menichelli D, Antonucci E, Gazzaniga G et al.. “Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis.” Journal of the American Heart Association (2025). PMID: 40519207 ↗

    L2TRIAL_NONRANDOMCited in: Management of Congestion and Comorbidities
  135. [135]

    Khan MS, Sauer AJ, Green CL et al.. “Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial.” American heart journal (2025). PMID: 40473009 ↗

    L5TRIAL_NONRANDOMCited in: Management of Congestion and Comorbidities
  136. [136]

    Cannata A, Crespo-Leiro MG, Bromage DI et al.. “Heart failure with reduced ejection fraction.” Lancet (London, England) (2026). PMID: 41319669 ↗

    L5REVIEW_NARRATIVECited in: Management of Congestion and Comorbidities
  137. [137]

    Boehmer AA, Ehrlich JR, Nattel S. “Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction: New Insights and Unresolved Questions.” JACC. Clinical electrophysiology (2025). PMID: 41231179 ↗

    L5REVIEW_NARRATIVECited in: Management of Congestion and Comorbidities
  138. [138]

    Lisi DL, Gaddis K, Abdou MH. “Heart Failure Pharmacotherapy.” The Medical clinics of North America (2025). PMID: 41136062 ↗

    L5REVIEW_NARRATIVECited in: Management of Congestion and Comorbidities
  139. [139]

    Beavers CJ, Greene SJ. “Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management.” Heart failure reviews (2025). PMID: 40841869 ↗

    L5REVIEW_NARRATIVECited in: Management of Congestion and Comorbidities
  140. [140]

    Gauer RL, Rifaat A, Foulkrod AM. “Heart Failure With Reduced Ejection Fraction: Medical Management.” American family physician (2025). PMID: 40834370 ↗

    L5REVIEW_NARRATIVECited in: Management of Congestion and Comorbidities
  141. [141]

    Sahana U, Wehland M, Simonsen U et al.. “A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure.” International journal of molecular sciences (2023). PMID: 37511587 ↗

    L1SR_OBSCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  142. [142]

    Ghazi L, Yamamoto Y, Riello RJ et al.. “Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.” Journal of the American College of Cardiology (2022). PMID: 35385798 ↗

    L1RCTCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  143. [143]

    Teerlink JR, Diaz R, Felker GM et al.. “Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.” The New England journal of medicine (2021). PMID: 33185990 ↗

    L1RCTCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  144. [144]

    Sephien A, Dayto DC, Reljic T et al.. “Efficacy of Decision Aids in The Use of Left Ventricular Assist Device in Patients With Advanced Heart Failure: A Systematic Review and Meta-Analysis of Randomized Control Trials.” The American journal of cardiology (2024). PMID: 37979637 ↗

    L1SR_OBSCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  145. [145]

    Muk B, Vámos M, Bógyi P et al.. “The impact of serum concentration-guided digoxin therapy on mortality of heart failure patients: A long-term follow-up, propensity-matched cohort study.” Clinical cardiology (2020). PMID: 33140454 ↗

    L3COHORTCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  146. [146]

    Hitzeroth J, Mpe M, Klug E et al.. “2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines.” South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (2020). PMID: 32880257 ↗

    L1GUIDELINECited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  147. [147]

    Xie L, Song S, Li S et al.. “Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS study): study protocol for a multicentric, prospective, randomized controlled clinical trial.” Trials (2023). PMID: 37158922 ↗

    L5TRIAL_NONRANDOMCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  148. [148]

    Tycińska A, Gierlotka M, Bartuś S et al.. “Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design.” Advances in medical sciences (2022). PMID: 34656873 ↗

    L5TRIAL_NONRANDOMCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  149. [149]

    Geavlete O, Ambrosy AP, Skowronski J et al.. “The DIGIT-HF trial and the Mihai Gheorghiade legacy: time to reconsider cardiac glycosides as effective therapy in HFrEF.” Heart failure reviews (2026). PMID: 41507435 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant, Prognosis, Monitoring, and Palliative Care
  150. [150]

    Kim R, Kittipibul V, Bhatt S et al.. “Device-based therapies for heart failure with preserved ejection fraction.” Heart failure reviews (2025). PMID: 40180634 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  151. [151]

    Riccardi M, Sammartino AM, Adamo M et al.. “Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction?” Heart failure reviews (2023). PMID: 37198505 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  152. [152]

    Trum M, Riechel J, Wagner S. “Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na+?” International journal of molecular sciences (2021). PMID: 34360742 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  153. [153]

    Mwansa H, Lewsey S, Mazimba S et al.. “Racial/Ethnic and Gender Disparities in Heart Failure with Reduced Ejection Fraction.” Current heart failure reports (2021). PMID: 33666856 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  154. [154]

    Hashemi-Shahri SH, Aghajanloo A, Ghavami V et al.. “Digoxin and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction (HFpEF) Patients: A Systematic Review and Meta- Analysis.” Current drug targets (2023). PMID: 36065922 ↗

    L1SR_OBSCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  155. [155]

    Bao J, Kan R, Chen J et al.. “Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.” Pharmacological research (2021). PMID: 33766629 ↗

    L1SR_OBSCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  156. [156]

    Jin C, Hsu J, Frenkel D et al.. “Unique technique to relieve left ventricular assist device electromagnetic interference with an implantable cardioverter defibrillator.” Journal of cardiovascular electrophysiology (2021). PMID: 33345375 ↗

    L4CASE_REPORTCited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  157. [157]

    Schroeder SE, Pozehl BJ, Alonso WW. “Frailty Assessment in Heart Failure and Ventricular Assist Device Populations: A Review from the United States.” Heart & lung : the journal of critical care (2021). PMID: 34433112 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  158. [158]

    Bernier TD, Buckley LF. “Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.” Journal of cardiovascular pharmacology (2021). PMID: 33165138 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: Inotropes, LVAD, and Transplant
  159. [159]

    Shen L, Shen L, Cheang I et al.. “The efficacy and safety of qiliqiangxin according to baseline ejection fraction in patients with heart failure and reduced ejection fraction in QUEST.” European journal of heart failure (2026). PMID: 41771073 ↗

    L2RCTCited in: Acute Decompensated HFrEF (ADHF), Prognosis, Monitoring, and Palliative Care
  160. [160]

    Westerhout CM, Alemayehu W, Cohen-Solal A et al.. “Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.” ESC heart failure (2025). PMID: 40977249 ↗

    L2RCTCited in: Acute Decompensated HFrEF (ADHF)
  161. [161]

    Butler J, McMullan CJ, Anstrom KJ et al.. “Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.” Lancet (London, England) (2025). PMID: 40897189 ↗

    L1RCTCited in: Acute Decompensated HFrEF (ADHF)
  162. [162]

    Zannad F, Reddy YNV, Barash I et al.. “Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.” Journal of the American College of Cardiology (2025). PMID: 40892609 ↗

    L2RCTCited in: Acute Decompensated HFrEF (ADHF)
  163. [163]

    Butler J, Fioretti F, McMullan CJ et al.. “Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.” European heart journal (2026). PMID: 40884032 ↗

    L2RCTCited in: Acute Decompensated HFrEF (ADHF)
  164. [164]

    Kobayashi M, Bayes-Genis A, Duarte K et al.. “Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.” European heart journal (2025). PMID: 40737218 ↗

    L2RCTCited in: Acute Decompensated HFrEF (ADHF)
  165. [165]

    Wang N, Hibbert T, Ishak S et al.. “Surrogate markers of clinical endpoints in clinical trials of heart failure.” European journal of heart failure (2026). PMID: 41771091 ↗

    L1TRIAL_NONRANDOMCited in: Acute Decompensated HFrEF (ADHF)
  166. [166]

    Irlik K, Piaśnik J, Hendel M et al.. “Mortality and heart failure hospitalizations in heart failure with preserved ejection fraction compared to heart failure with reduced ejection fraction: a systematic review and meta-analysis.” ESC heart failure (2026). PMID: 41711724 ↗

    L2SR_OBSCited in: Acute Decompensated HFrEF (ADHF)
  167. [167]

    Castelletti F, Bianco E, Fabro G et al.. “Practical considerations for the use of vericiguat in older patients with heart failure and reduced ejection fraction.” European journal of clinical investigation (2026). PMID: 41714297 ↗

    L5REVIEW_NARRATIVECited in: Acute Decompensated HFrEF (ADHF)
  168. [168]

    Saito S, Temma T, Nagai T et al.. “Prognostic Value of Mid-Range QRS Duration in Patients With Heart Failure With Reduced Ejection Fraction.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 42036323 ↗

    L2OTHERCited in: Acute Decompensated HFrEF (ADHF)
  169. [169]

    Pichardo-Gonzalez R, Le KK, Tran QK et al.. “Trends in acute decompensated heart failure admissions and healthcare costs in U.S. emergency departments.” The American journal of emergency medicine (2026). PMID: 41806537 ↗

    L2OTHERCited in: Acute Decompensated HFrEF (ADHF)
  170. [170]

    Lund LH, Maggioni AP, Crespo-Leiro MG et al.. “Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.” European heart journal (2026). PMID: 41736503 ↗

    L2OTHERCited in: Acute Decompensated HFrEF (ADHF)
  171. [171]

    Wali RK, Iyengar M, Beck GJ et al.. “Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.” Circulation. Heart failure (2011). PMID: 21036889 ↗

    L1SR_MA_RCTCited in: Landmark Trials and Key Evidence
  172. [172]

    McMurray JJ, Packer M, Desai AS et al.. “Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).” European journal of heart failure (2013). PMID: 23563576 ↗

    L5RCTCited in: Landmark Trials and Key Evidence
  173. [173]

    Januzzi JL, Zannad F, Anker SD et al.. “Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.” Journal of the American College of Cardiology (2021). PMID: 34556318 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  174. [174]

    Böhm M, Anker SD, Butler J et al.. “Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.” Journal of the American College of Cardiology (2021). PMID: 34556320 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  175. [175]

    Bowling CB, Sanders PW, Allman RM et al.. “Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial.” International journal of cardiology (2013). PMID: 22257685 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  176. [176]

    Ghali JK, Wikstrand J, Van Veldhuisen DJ et al.. “The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF).” Journal of cardiac failure (2009). PMID: 19398079 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  177. [177]

    Sabe MA, Jacob MS, Taylor DO. “A new class of drugs for systolic heart failure: The PARADIGM-HF study.” Cleveland Clinic journal of medicine (2015). PMID: 26469827 ↗

    L5RCTCited in: Landmark Trials and Key Evidence
  178. [178]

    Kondo T, Butt JH, Curtain JP et al.. “Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.” Circulation. Heart failure (2023). PMID: 37886880 ↗

    L1OTHERCited in: Landmark Trials and Key Evidence
  179. [179]

    Wikstrand J, Wedel H, Castagno D et al.. “The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.” Journal of internal medicine (2014). PMID: 24118421 ↗

    L1OTHERCited in: Landmark Trials and Key Evidence
  180. [180]

    Zacharski M, Tomaszek A, Kiczak L et al.. “Catabolic/Anabolic Imbalance Is Accompanied by Changes of Left Ventricular Steroid Nuclear Receptor Expression in Tachycardia-Induced Systolic Heart Failure in Male Pigs.” Journal of cardiac failure (2021). PMID: 33450412 ↗

    L5OTHERCited in: Landmark Trials and Key Evidence
  181. [181]

    Filippatos G, Farmakis D, Parissis J et al.. “Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice.” BMC medicine (2015). PMID: 25849438 ↗

    L5OTHERCited in: Landmark Trials and Key Evidence
  182. [182]

    Lillyblad MP. “Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.” The Annals of pharmacotherapy (2015). PMID: 26175499 ↗

    L5REVIEW_NARRATIVECited in: Landmark Trials and Key Evidence
  183. [183]

    Banach J, Grochowska M, Gackowska L et al.. “Melanoma cell adhesion molecule as an emerging biomarker with prognostic significance in systolic heart failure.” Biomarkers in medicine (2016). PMID: 27355366 ↗

    L2OTHERCited in: Landmark Trials and Key Evidence
  184. [184]

    Lu BN, Davis LE. “Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.” JAAPA : official journal of the American Academy of Physician Assistants (2018). PMID: 29957605 ↗

    L5OTHERCited in: Landmark Trials and Key Evidence
  185. [185]

    Widimský J. “[The new drug is much more effective than ACE inhibitors in chronic heart failure].” Vnitrni lekarstvi (2015). PMID: 25813256 ↗

    L5REVIEW_NARRATIVECited in: Landmark Trials and Key Evidence
  186. [186]

    Savarese G, Basile C, Mebazaa A et al.. “Ten years real-world experience with sacubitril/valsartan in patients with heart failure with reduced ejection fraction.” ESC heart failure (2026). PMID: 41920861 ↗

    L2SR_OBSCited in: Prognosis, Monitoring, and Palliative Care
  187. [187]

    Van Tassell BW, Golino M, Canada JM et al.. “Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra.” Circulation. Heart failure (2026). PMID: 41431894 ↗

    L1RCTCited in: Prognosis, Monitoring, and Palliative Care
  188. [188]

    Okuno Y, Hanatani S, Ogata F et al.. “High Human Epididymis Protein 4 Levels Are Associated With Lower Systolic Function and Poor Prognosis in Heart Failure With Reduced Ejection Fraction.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 41922277 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis, Monitoring, and Palliative Care
  189. [189]

    Li Y, Mao T, Qu X et al.. “Efficacy and safety of Qiliqiangxin capsule as adjunctive therapy in heart failure with reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials.” Journal of ethnopharmacology (2026). PMID: 41500350 ↗

    L1SR_MA_RCTCited in: Prognosis, Monitoring, and Palliative Care
  190. [190]

    Kozhevnikova MV, Emelianov AV, Zheleznykh EA et al.. “Impact of Digital Remote Monitoring on the Optimization of Guideline-Directed Medical Therapy Titration in Heart Failure With Reduced Ejection Fraction.” Kardiologiia (2026). PMID: 41925172 ↗

    L1RCTCited in: Prognosis, Monitoring, and Palliative Care
  191. [191]

    Rodés-Cabau J, Mengi S, Salaun E et al.. “Transcatheter edge-to-edge repair in secondary mitral regurgitation.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2025). PMID: 41489737 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Monitoring, and Palliative Care
  192. [192]

    Stahl ME, Weeldreyer NR, MacNamara JP et al.. “Exercise Rehabilitation for Heart Failure and Associated Cardiomyopathies.” Current cardiology reports (2025). PMID: 41329236 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Monitoring, and Palliative Care

Revision History

All updates applied to this page

Loading revisions…